Literature DB >> 12974396

Snake venom as therapeutic agents: from toxin to drug development.

Sanjoy Kumar Pal1, Aparna Gomes, S C Dasgupta, Antony Gomes.   

Abstract

Snake bite injuries and death are socio-medical problems of considerable magnitude. In India a large number of people suffer and die every year due to snake venom poisoning. Snake venom, though greatly feared, is a natural biological resource, containing several components that could be of potential therapeutic value. Use of snake venom in different pathophysiological conditions has been mentioned in Ayurveda, homeopathy and folk medicine. It is well known that snake venom is complex mixture of enzymes, peptides and proteins of low molecular mass with specific chemical and biological activities. Snake venom contains several neurotoxic, cardiotoxic, cytotoxic, nerve growth factor, lectins, disintrigrins, haemorrhagins and many other different enzymes. These proteins not only inflict death to animals and humans, but can also be used for the treatment of thrombosis, arthritis, cancer and many other diseases. An overview of various snake venom components that have prospects in health and diseases are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12974396

Source DB:  PubMed          Journal:  Indian J Exp Biol        ISSN: 0019-5189            Impact factor:   0.818


  17 in total

1.  Evaluation of cytotoxic activities of snake venoms toward breast (MCF-7) and skin cancer (A-375) cell lines.

Authors:  Michael J Bradshaw; Anthony J Saviola; Elizabeth Fesler; Stephen P Mackessy
Journal:  Cytotechnology       Date:  2014-11-19       Impact factor: 2.058

Review 2.  The spectral networks paradigm in high throughput mass spectrometry.

Authors:  Adrian Guthals; Jeramie D Watrous; Pieter C Dorrestein; Nuno Bandeira
Journal:  Mol Biosyst       Date:  2012-10

3.  Effect of Ottoman Viper (Montivipera xanthina (Gray, 1849)) Venom on Various Cancer Cells and on Microorganisms.

Authors:  Husniye Tansel Yalcın; Mehmet Ozgün Ozen; Bayram Gocmen; Ayse Nalbantsoy
Journal:  Cytotechnology       Date:  2013-02-05       Impact factor: 2.058

4.  Nanoparticle-conjugated animal venom-toxins and their possible therapeutic potential.

Authors:  Archita Biswas; Aparna Gomes; Jayeeta Sengupta; Poulami Datta; Santiswarup Singha; Anjan Kr Dasgupta; Antony Gomes
Journal:  J Venom Res       Date:  2012-10-23

5.  Snake Venom: Any Clue for Antibiotics and CAM?

Authors:  Deivy Clementino de Lima; Paula Alvarez Abreu; Cícero Carlos de Freitas; Dilvani Oliveira Santos; Rodrigo Oliveira Borges; Tereza Cristina Dos Santos; Lúcio Mendes Cabral; Carlos R Rodrigues; Helena Carla Castro
Journal:  Evid Based Complement Alternat Med       Date:  2005-03       Impact factor: 2.629

Review 6.  Pharmacological aspects of Nerium indicum Mill: A comprehensive review.

Authors:  Priyankar Dey; Tapas Kumar Chaudhuri
Journal:  Pharmacogn Rev       Date:  2014-07

7.  Cobra cytotoxins: structural organization and antibacterial activity.

Authors:  P V Dubovskii; Y N Utkin
Journal:  Acta Naturae       Date:  2014-07       Impact factor: 1.845

8.  Canopy Venom: Proteomic Comparison among New World Arboreal Pit-Viper Venoms.

Authors:  Jordan Debono; Chip Cochran; Sanjaya Kuruppu; Amanda Nouwens; Niwanthi W Rajapakse; Minami Kawasaki; Kelly Wood; James Dobson; Kate Baumann; Mahdokht Jouiaei; Timothy N W Jackson; Ivan Koludarov; Dolyce Low; Syed A Ali; A Ian Smith; Andrew Barnes; Bryan G Fry
Journal:  Toxins (Basel)       Date:  2016-07-08       Impact factor: 4.546

9.  Vasorelaxin: a novel arterial smooth muscle-relaxing eicosapeptide from the skin secretion of the Chinese piebald odorous frog (Odorrana schmackeri).

Authors:  Yuxin Wu; Lei Wang; Chen Lin; Yan Lin; Mei Zhou; Liang Chen; Brian Connolly; Yingqi Zhang; Tianbao Chen; Chris Shaw
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

10.  Suppression of Inflammation and Arthritis by Orally Administrated Cardiotoxin from Naja naja atra.

Authors:  Cao-Xin Chen; Jie-Yu Chen; Jian-Qun Kou; Yin-Li Xu; Shu-Zhi Wang; Qi Zhu; Lu Yang; Zheng-Hong Qin
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.